Skip to content

7T Brain MRI Scan for Micro-brain Metastasis (microBM) Detection for Patients With Small-cell Lung Cancer (SCLC), Who Decline Prophylactic Cranial Irradiation (PCI)

7T Brain MRI Scan for Micro-brain Metastasis (microBM) Detection for Patients With Small-cell Lung Cancer (SCLC), Who Decline Prophylactic Cranial Irradiation (PCI)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07175077
Enrollment
20
Registered
2025-09-16
Start date
2025-11-01
Completion date
2027-09-30
Last updated
2025-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Small-cell Lung Cancer, Brain Metastases

Brief summary

Comparison of a 7t MRI to standard of care 1.5t/3t MRI scans to determine if earlier detection of brain metastases are possible on a 7t.

Detailed description

This study is looking at patients diagnosed with small-cell lung cancer & have declined prophylactic cranial irradiation. Patients must have had a 1.5t/3t MRI performed within 4 weeks of consenting to the trial that was negative for brain metastases. Patients will then undergo a 7t MRI & be followed for their standard of care scans for 12 months or until confirmed metastases are detected. Once a patient has confirmed brain mets, their standard of care scans will be used for an analysis compared to the 7t scan to determine if earlier detection of brain micro metastases are feasible.

Interventions

DEVICE7t MRI

7t brain MRI followed by up to 12 months of standard of care 1.5t/3t MRI scans

Sponsors

Siemens Medical Solutions
CollaboratorINDUSTRY
University of Missouri-Columbia
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient must have a histologically confirmed diagnosis of small-cell lung cancer (SCLC). • Patient must have an MRI of the brain, performed within 4 weeks prior to consent, documenting no evidence of brain metastases or leptomeningeal disease. * Patient also must not have a history of brain metastases or leptomeningeal disease. * Patient must refuse PCI and agree to surveillance with brain MRI scans (1.5T/3T). * Patient must be ≥ 18 years of age. * Patient must have ECOG Performance Status of 0-2 * Patients must be able to tolerate the 7T MRI

Exclusion criteria

* Patient must not have a contraindication to an MRI, such as implanted metal devices or foreign bodies. * Patient must not have a contraindication to gadolinium contrast administration during MR imaging. * Patient must not have other metastatic malignancies requiring current active treatment. * Pregnant patients are excluded. Pregnancy status will be confirmed verbally.

Design outcomes

Primary

MeasureTime frameDescription
7t MRI Brain Metastases Detection3, 6, 9, 12 months after 7T MRIComparison of 7t MRI to 1.5t/3t to determine if the 7t MRI was able to detect metastases prior to a 1.5t/3t MRI

Countries

United States

Contacts

Primary ContactBrooke McDaniel
mcdanielbl@health.missouri.edu573-884-7488

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026